CovidChloroV1, Main, Corpus, bibRecord, 001963

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.

Identifieur interne : 001963 ( Main/Corpus ); précédent : 001962; suivant : 001964

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.

Auteurs : Phulen Sarma ; Hardeep Kaur ; Harish Kumar ; Dhruv Mahendru ; Pramod Avti ; Anusuya Bhattacharyya ; Manisha Prajapat ; Nishant Shekhar ; Subodh Kumar ; Rahul Singh ; Ashutosh Singh ; Deba Prasad Dhibar ; Ajay Prakash ; Bikash Medhi

Source :

Journal of medical virology [ 1096-9071 ] ; 2020.

RBID : pubmed:32297988

English descriptors

KwdEn :
- Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (growth & development), Betacoronavirus (pathogenicity), COVID-19 (MeSH), Clinical Trials as Topic (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (metabolism), Drug Therapy, Combination (methods), Humans (MeSH), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (metabolism), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH), Viral Load (drug effects), Virus Replication (drug effects).
MESH :
- chemical , therapeutic use : Antiviral Agents, Azithromycin, Hydroxychloroquine.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus, Viral Load, Virus Replication.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- growth & development : Betacoronavirus.
- metabolism : Coronavirus Infections, Pneumonia, Viral.
- methods : Drug Therapy, Combination.
- pathogenicity : Betacoronavirus.
- COVID-19, Clinical Trials as Topic, Humans, Pandemics, SARS-CoV-2, Treatment Outcome.

Abstract

Following the demonstration of the efficacy of hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 in vitro, many trials started to evaluate its efficacy in clinical settings. However, no systematic review and meta-analysis have addressed the issue of the safety and efficacy of hydroxychloroquine (HCQ) in coronavirus disease 2019. We conducted a systematic review and meta-analysis with the objectives of evaluation of safety and efficacy of HCQ alone or in combination in terms of "time to clinical cure," "virological cure," "death or clinical worsening of disease," "radiological progression," and safety. RevMan was used for meta-analysis. We searched 16 literature databases out of which seven studies (n = 1358) were included in the systematic review. In terms of clinical cure, two studies reported possible benefit in "time to body temperature normalization" and one study reported less "cough days" in the HCQ arm. Treatment with HCQ resulted in less number of cases showing the radiological progression of lung disease (odds ratio [OR], 0.31, 95% confidence interval [CI], 0.11-0.9). No difference was observed in virological cure (OR, 2.37, 95% CI, 0.13-44.53), death or clinical worsening of disease (OR, 1.37, 95% CI, 1.37-21.97), and safety (OR, 2.19, 95% CI, 0.59-8.18), when compared with the control/conventional treatment. Five studies reported either the safety or efficacy of HCQ + azithromycin. Although seems safe and effective, more data are required for a definitive conclusion. HCQ seems to be promising in terms of less number of cases with radiological progression with a comparable safety profile to control/conventional treatment. We need more data to come to a definite conclusion.

DOI: 10.1002/jmv.25898
PubMed: 32297988
PubMed Central: PMC7262144

Links to Exploration step

pubmed:32297988

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.</title>
<author><name sortKey="Sarma, Phulen" sort="Sarma, Phulen" uniqKey="Sarma P" first="Phulen" last="Sarma">Phulen Sarma</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kaur, Hardeep" sort="Kaur, Hardeep" uniqKey="Kaur H" first="Hardeep" last="Kaur">Hardeep Kaur</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumar, Harish" sort="Kumar, Harish" uniqKey="Kumar H" first="Harish" last="Kumar">Harish Kumar</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mahendru, Dhruv" sort="Mahendru, Dhruv" uniqKey="Mahendru D" first="Dhruv" last="Mahendru">Dhruv Mahendru</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Avti, Pramod" sort="Avti, Pramod" uniqKey="Avti P" first="Pramod" last="Avti">Pramod Avti</name>
<affiliation><nlm:affiliation>Department of Biophysics, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bhattacharyya, Anusuya" sort="Bhattacharyya, Anusuya" uniqKey="Bhattacharyya A" first="Anusuya" last="Bhattacharyya">Anusuya Bhattacharyya</name>
<affiliation><nlm:affiliation>Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Prajapat, Manisha" sort="Prajapat, Manisha" uniqKey="Prajapat M" first="Manisha" last="Prajapat">Manisha Prajapat</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shekhar, Nishant" sort="Shekhar, Nishant" uniqKey="Shekhar N" first="Nishant" last="Shekhar">Nishant Shekhar</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumar, Subodh" sort="Kumar, Subodh" uniqKey="Kumar S" first="Subodh" last="Kumar">Subodh Kumar</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Singh, Rahul" sort="Singh, Rahul" uniqKey="Singh R" first="Rahul" last="Singh">Rahul Singh</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Singh, Ashutosh" sort="Singh, Ashutosh" uniqKey="Singh A" first="Ashutosh" last="Singh">Ashutosh Singh</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dhibar, Deba Prasad" sort="Dhibar, Deba Prasad" uniqKey="Dhibar D" first="Deba Prasad" last="Dhibar">Deba Prasad Dhibar</name>
<affiliation><nlm:affiliation>Department of Internal medicine, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Prakash, Ajay" sort="Prakash, Ajay" uniqKey="Prakash A" first="Ajay" last="Prakash">Ajay Prakash</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Medhi, Bikash" sort="Medhi, Bikash" uniqKey="Medhi B" first="Bikash" last="Medhi">Bikash Medhi</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32297988</idno>
<idno type="pmid">32297988</idno>
<idno type="doi">10.1002/jmv.25898</idno>
<idno type="pmc">PMC7262144</idno>
<idno type="wicri:Area/Main/Corpus">001963</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001963</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.</title>
<author><name sortKey="Sarma, Phulen" sort="Sarma, Phulen" uniqKey="Sarma P" first="Phulen" last="Sarma">Phulen Sarma</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kaur, Hardeep" sort="Kaur, Hardeep" uniqKey="Kaur H" first="Hardeep" last="Kaur">Hardeep Kaur</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumar, Harish" sort="Kumar, Harish" uniqKey="Kumar H" first="Harish" last="Kumar">Harish Kumar</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mahendru, Dhruv" sort="Mahendru, Dhruv" uniqKey="Mahendru D" first="Dhruv" last="Mahendru">Dhruv Mahendru</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Avti, Pramod" sort="Avti, Pramod" uniqKey="Avti P" first="Pramod" last="Avti">Pramod Avti</name>
<affiliation><nlm:affiliation>Department of Biophysics, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bhattacharyya, Anusuya" sort="Bhattacharyya, Anusuya" uniqKey="Bhattacharyya A" first="Anusuya" last="Bhattacharyya">Anusuya Bhattacharyya</name>
<affiliation><nlm:affiliation>Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Prajapat, Manisha" sort="Prajapat, Manisha" uniqKey="Prajapat M" first="Manisha" last="Prajapat">Manisha Prajapat</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shekhar, Nishant" sort="Shekhar, Nishant" uniqKey="Shekhar N" first="Nishant" last="Shekhar">Nishant Shekhar</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumar, Subodh" sort="Kumar, Subodh" uniqKey="Kumar S" first="Subodh" last="Kumar">Subodh Kumar</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Singh, Rahul" sort="Singh, Rahul" uniqKey="Singh R" first="Rahul" last="Singh">Rahul Singh</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Singh, Ashutosh" sort="Singh, Ashutosh" uniqKey="Singh A" first="Ashutosh" last="Singh">Ashutosh Singh</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dhibar, Deba Prasad" sort="Dhibar, Deba Prasad" uniqKey="Dhibar D" first="Deba Prasad" last="Dhibar">Deba Prasad Dhibar</name>
<affiliation><nlm:affiliation>Department of Internal medicine, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Prakash, Ajay" sort="Prakash, Ajay" uniqKey="Prakash A" first="Ajay" last="Prakash">Ajay Prakash</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Medhi, Bikash" sort="Medhi, Bikash" uniqKey="Medhi B" first="Bikash" last="Medhi">Bikash Medhi</name>
<affiliation><nlm:affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of medical virology</title>
<idno type="eISSN">1096-9071</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (growth & development)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>COVID-19 (MeSH)</term>
<term>Clinical Trials as Topic (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (metabolism)</term>
<term>Drug Therapy, Combination (methods)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (metabolism)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Viral Load (drug effects)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Viral Load</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy, Combination</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Following the demonstration of the efficacy of hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 in vitro, many trials started to evaluate its efficacy in clinical settings. However, no systematic review and meta-analysis have addressed the issue of the safety and efficacy of hydroxychloroquine (HCQ) in coronavirus disease 2019. We conducted a systematic review and meta-analysis with the objectives of evaluation of safety and efficacy of HCQ alone or in combination in terms of "time to clinical cure," "virological cure," "death or clinical worsening of disease," "radiological progression," and safety. RevMan was used for meta-analysis. We searched 16 literature databases out of which seven studies (n = 1358) were included in the systematic review. In terms of clinical cure, two studies reported possible benefit in "time to body temperature normalization" and one study reported less "cough days" in the HCQ arm. Treatment with HCQ resulted in less number of cases showing the radiological progression of lung disease (odds ratio [OR], 0.31, 95% confidence interval [CI], 0.11-0.9). No difference was observed in virological cure (OR, 2.37, 95% CI, 0.13-44.53), death or clinical worsening of disease (OR, 1.37, 95% CI, 1.37-21.97), and safety (OR, 2.19, 95% CI, 0.59-8.18), when compared with the control/conventional treatment. Five studies reported either the safety or efficacy of HCQ + azithromycin. Although seems safe and effective, more data are required for a definitive conclusion. HCQ seems to be promising in terms of less number of cases with radiological progression with a comparable safety profile to control/conventional treatment. We need more data to come to a definite conclusion.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32297988</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>02</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>92</Volume>
<Issue>7</Issue>
<PubDate><Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Journal of medical virology</Title>
<ISOAbbreviation>J Med Virol</ISOAbbreviation>
</Journal>
<ArticleTitle>Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.</ArticleTitle>
<Pagination><MedlinePgn>776-785</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.25898</ELocationID>
<Abstract><AbstractText>Following the demonstration of the efficacy of hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 in vitro, many trials started to evaluate its efficacy in clinical settings. However, no systematic review and meta-analysis have addressed the issue of the safety and efficacy of hydroxychloroquine (HCQ) in coronavirus disease 2019. We conducted a systematic review and meta-analysis with the objectives of evaluation of safety and efficacy of HCQ alone or in combination in terms of "time to clinical cure," "virological cure," "death or clinical worsening of disease," "radiological progression," and safety. RevMan was used for meta-analysis. We searched 16 literature databases out of which seven studies (n = 1358) were included in the systematic review. In terms of clinical cure, two studies reported possible benefit in "time to body temperature normalization" and one study reported less "cough days" in the HCQ arm. Treatment with HCQ resulted in less number of cases showing the radiological progression of lung disease (odds ratio [OR], 0.31, 95% confidence interval [CI], 0.11-0.9). No difference was observed in virological cure (OR, 2.37, 95% CI, 0.13-44.53), death or clinical worsening of disease (OR, 1.37, 95% CI, 1.37-21.97), and safety (OR, 2.19, 95% CI, 0.59-8.18), when compared with the control/conventional treatment. Five studies reported either the safety or efficacy of HCQ + azithromycin. Although seems safe and effective, more data are required for a definitive conclusion. HCQ seems to be promising in terms of less number of cases with radiological progression with a comparable safety profile to control/conventional treatment. We need more data to come to a definite conclusion.</AbstractText>
<CopyrightInformation>© 2020 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarma</LastName>
<ForeName>Phulen</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kaur</LastName>
<ForeName>Hardeep</ForeName>
<Initials>H</Initials>
<Identifier Source="ORCID">0000-0003-2419-1887</Identifier>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kumar</LastName>
<ForeName>Harish</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mahendru</LastName>
<ForeName>Dhruv</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Avti</LastName>
<ForeName>Pramod</ForeName>
<Initials>P</Initials>
<Identifier Source="ORCID">0000-0001-5603-4523</Identifier>
<AffiliationInfo><Affiliation>Department of Biophysics, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bhattacharyya</LastName>
<ForeName>Anusuya</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Prajapat</LastName>
<ForeName>Manisha</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shekhar</LastName>
<ForeName>Nishant</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kumar</LastName>
<ForeName>Subodh</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Singh</LastName>
<ForeName>Rahul</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Singh</LastName>
<ForeName>Ashutosh</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dhibar</LastName>
<ForeName>Deba Prasad</ForeName>
<Initials>DP</Initials>
<AffiliationInfo><Affiliation>Department of Internal medicine, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Prakash</LastName>
<ForeName>Ajay</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Medhi</LastName>
<ForeName>Bikash</ForeName>
<Initials>B</Initials>
<Identifier Source="ORCID">0000-0002-4017-641X</Identifier>
<AffiliationInfo><Affiliation>Department of Pharmacology, Post Graduate Institute of Medical Research, Chandigarh, India.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Med Virol</MedlineTA>
<NlmUniqueID>7705876</NlmUniqueID>
<ISSNLinking>0146-6615</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Med Virol. 2020 Nov;92(11):2322-2324</RefSource>
<PMID Version="1">32401368</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>J Med Virol. 2020 Jun 24;:null</RefSource>
<PMID Version="1">32579244</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">2019-nCoV</Keyword>
<Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">SARS CoV-2</Keyword>
<Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="Y">meta-analysis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32297988</ArticleId>
<ArticleId IdType="doi">10.1002/jmv.25898</ArticleId>
<ArticleId IdType="pmc">PMC7262144</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Pharmacol. 2020 Jan-Feb;52(1):56-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32201449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuropsychiatr Dis Treat. 2018 Jul 11;14:1811-1820</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30022830</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2016 Oct 12;355:i4919</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27733354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Epidemiol. 2020 Jan;117:99-108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31589952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 May 18;:1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32266867</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jul;92(7):776-785</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32297988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 May;177:104762</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32201439</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Cell Biol. 2020 May 18;12(4):322-325</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32236562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101738</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32387409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Jun 14;8(6):e65913</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23799062</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001963 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001963 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32297988
   |texte=   Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32297988" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki